

CORRECTION Open Access

# TRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis

Amelie Fassbender, Peter Simsa, Cleophas M Kyama, Etienne Waelkens, Attila Mihalyi, Christel Meuleman, Olivier Gevaert, Raf Van de Plas, Bart de Moor and Thomas M D'Hooghe<sup>1,2,3,4\*</sup>

Since publication of our article [1], we have realised that we did not include the full data in Table 1 and missed the word (TOF) in the result/discussion section. We have provided here the adapted sentence and another version of the table, including all the information intended.

### **Results/Discussion**

"Therefore, we plan to repeat this study in a larger sample size including well defined endometrial samples obtained during menstrual, follicular and secretory phase, to validate the reproducibility of SELDI-TOF MS technology in these samples and to identify the protein

Table 1 The representative molecular weights of the proteins identified in the mRNA Microarray study [Thirteen] [2]

Protein	Mass in Da	
Osteoglycin (OGN/4969)	33,922	
Interleukin-6 signal transducer (IL6ST/3572)	isoform 1 103,537 isoform 2 37,499	
Cytochrome P450, Family 2, Subfamily J, polypeptide 2 (CYP2J2/1573)	57,611	
Carboxypeptidase E (CPE/1363)	53,151	
Fibronectin 1 (FN1/2335)	different isoforms	
	1. 262,607	
	2. 71,943	
	3. 259,198	
	4. 222,944	
	5. 243,316	
	6. 240,477	
	7. 268,894	
	8. 252,793	
	9. 246,670	
	10. 239,608	
	11. 262,388	
	12. 221,274	
	13. 249,304	
	14. 249,384	

<sup>\*</sup> Correspondence: thomas.dhooghe@uzleuven.be

<sup>&</sup>lt;sup>1</sup>Leuven University Fertility Centre, Department of Obstetrics & Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium






Table 1 The representative molecular weights of the proteins identified in the mRNA Microarray study [Thirteen] [2] (Continued)

	15. 272,302	
Synuclein, gamma (SNCG/6623)	13,331	
BAI1-associated protein 2 (BAIAP2/10458)	different isoforms	
	1. 60,868	
	2. 59,014	
	3. 56,626	
	4. 57,359	
	5. 57,445	
	6. 57,430	
Protocadherin 17 (PCDH17/27253)	different isoforms	
	1. 126,229	
	2. 96,570	
Protein tyrosine phosphatase, receptor type, R (PTPRR/5801)	Alpha 73,834 Da Gamma 46,581Da Delta 51,046Da	

peaks observed after proteomic analysis, which are expensive and labour intense requiring High-performance liquid chromatography or high-pressure liquid chromatography (HPLC) and matrix assisted laser desorption ionization Time-of-Flight-Mass Spectrometry (MALDI-TOF/TOF MS)."

### **Author details**

<sup>1</sup>Leuven University Fertility Centre, Department of Obstetrics & Gynaecology, University Hospital Gasthuisberg, Leuven, Belgium. <sup>2</sup>Division of Reproductive Health and Biology, Institute of Primate Research, P.O. Box 24481-00502 Karen, Nairobi, Kenya. <sup>3</sup>Biochemistry Section, Department of Molecular Cell Biology, Campus Gasthuisberg, Leuven, Belgium. <sup>4</sup>Department of Electrical Engineering, ESAT-SCD, K.U.Leuven, Kasteelpark-Arenberg 10, B-3001 Heverlee, Belgium.

Received: 29 March 2011 Accepted: 6 April 2011 Published: 6 April 2011

### References

- Fassbender Amelie, Simsa Peter, Kyama MCleophas, Waelkens Etienne, Mihalyi Attila, Meuleman Christel, Gevaert Olivier, Van de Plas Raf, de Moor Bart, D'Hooghe MThomas: TRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis. Reproductive Biology and Endocrinology 2010, 8:123.
- Sherwin JR, Sharkey AM, Mihalyi A, Simsa P, Catalano RD, D'Hooghe TM: Global gene analysis of late secretory phase, eutopic endometrium does not provide the basis for a minimally invasive test of endometriosis. Hum Reprod 2008, 23(5):1063-1068.

## doi:10.1186/1477-7827-9-44

Cite this article as: Fassbender *et al*: TRIzol treatment of secretory phase endometrium allows combined proteomic and mRNA microarray analysis of the same sample in women with and without endometriosis. *Reproductive Biology and Endocrinology* 2011 9:44.

# Submit your next manuscript to BioMed Central and take full advantage of:

- Convenient online submission
- Thorough peer review
- No space constraints or color figure charges
- Immediate publication on acceptance
- Inclusion in PubMed, CAS, Scopus and Google Scholar
- Research which is freely available for redistribution

Submit your manuscript at www.biomedcentral.com/submit

